A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb5871 in Patients with IgG4-Related Disease (INDIGO)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

07 Nov 2022 According to a Zenas BioPharma media release, the company has received proceeds of $118 million in connection with the issuance of Series B preferred shares. The funding was led by Enavate Sciences and included Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital as shareholders. The proceeds from the financing will be used to support this trial.
14 Nov 2020 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
11 Jun 2020 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com